Videos

Experts in genitourinary oncology review the treatment choices available after metastatic castration-resistant prostate cancer progression on abiraterone acetate + prednisone.

Jorge A. Garcia, MD, FA, describes the case of a 72-year-old man with metastatic castration-resistant prostate cancer.

Patrick G. Pilié, MD, presents data from the phase 3 PROSPER trial of enzalutamide, and Ganesh V Raj, MD, PhD, presents data from the phase 3 ARAMIS trial of darolutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC).

Ganesh V Raj, MD, PhD, presents data from the phase 3 SPARTAN trial of apalutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC).

Experts in genitourinary oncology discuss how they choose therapy for patients with long PSA doubling times in nonmetastatic castration-resistant prostate cancer (nmCRPC).

Experts in genitourinary oncology share how they decide between the 3 antiandrogen therapies for nonmetastatic castration-resistant prostate cancer: apalutamide, enzalutamide, and darolutamide.

Experts in genitourinary oncology share their methods and patient specific factors that aid in selecting therapy for nonmetastatic castration-resistant prostate cancer.

Ganesh V Raj, MD, PhD, and Mary-Ellen Taplin, MD, review the role of next-generation sequencing in nonmetastatic castration-resistant prostate cancer, and who qualifies based on NCCN guidelines.

Mary-Ellen Taplin, MD, reviews the criteria used to initiate androgen deprivation therapy in the setting of rising PSA syndrome for patients with nonmetastatic castration-resistant prostate cancer.

Ganesh V Raj, MD, PhD, shares his approach to radiation therapy in patients with nonmetastatic castration-resistant prostate cancer.

Experts in genitourinary oncology share their use of novel imaging in practice for nonmetastatic castration-resistant prostate cancer.

Jorge A. Garcia, MD, FACP, describes the case of a 57-year-old African American man with nonmetastatic castration-resistant prostate cancer, and Ganesh V Raj, MD, PhD, reviews how the MRI/TRUS fusion biopsy is becoming a mainstay in diagnosis.

Experts in genitourinary cancer review 2 clinical cases and address major changes in the management of patients with castration-resistant prostate cancer.

Tycel J. Phillips, MD, discusses the current treatment options for patients with marginal zone lymphoma.

Connie L. Batlevi, MD, PhD, discusses the efficacy of tazemetostat in patients with follicular lymphoma and an EZH2 mutation.

Jia Ruan, MD, PhD, discusses the results of the multicenter phase 2 trial of oral azacitidine plus cyclophosphamide, doxorubicin, vincristine, and prednisone as initial treatment in patients with peripheral T-cell lymphoma.

Dr Ticiana Leal, MD, highlights the approvals of new regiments in small cell lung cancer. However, she discusses the struggles physicians currently face, such as identifying predictive biomarkers used to select patients who may respond well to new treatment regiments.

Dr Ticiana Leal, MD, describes the choice to prescribe lurbinectedin in the second-line setting for the patient as well as her personal experience with the drug.

Dr Ticiana Leal, MD, discusses the role of topotecan and lurbinectedin as novel agents in second-line therapy for small cell lung cancer.

Dr Ticiana Leal, MD, lists the treatment options associated with first-line therapy and its relation to platinum sensitivity.

Dr Ticiana Leal, MD, comments on the treatment given, the effectiveness of treatment, and the future prognosis of this patient with small cell lung cancer.

Dr Ticiana Leal, MD, outlines the specific demographic and diagnosis of a patient with small cell lung cancer.

Ticiana Leal, MD, presents a case of a 61-year-old man with small cell lung cancer.

Marcia Brose, MD, PhD, discusses a global, non-interventional study that assessed the use of sorafenib as treatment of patients with asymptomatic radioiodine-refractory differentiated thyroid cancer.

Looking forward to further combinations and approaches for frontline and second-line therapy in advanced, unresectable hepatocellular carcinoma.

Efficacy, safety, and quality of life data from IMbrave150 have changed the standard of care for unresectable hepatocellular carcinoma.

Recent updates from the IMbrave150 study, which led to the FDA approval of frontline atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma [HCC].

Richard S. Finn, MD, provides an overview of the systemic treatment options for advanced unresectable hepatocellular carcinoma.

Defining resectability in hepatocellular carcinoma based on burden of liver disease and Child-Pugh score.

A review of prognostic factors and the importance of understanding underlying liver disease to help stage and treat patients with hepatocellular carcinoma.